Cargando…

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma

Regorafenib and nivolumab are drugs approved for second‐line treatment of patients with hepatocellular carcinoma (HCC) after sorafenib failure. However, the effectiveness of regorafenib and nivolumab following sorafenib has not been directly compared. This study retrospectively evaluated 373 patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Won‐Mook, Choi, Jonggi, Lee, Danbi, Shim, Ju Hyun, Lim, Young‐Suk, Lee, Han Chu, Chung, Young‐Hwa, Lee, Young‐Sang, Park, Sook Ryun, Ryu, Min‐Hee, Ryoo, Baek‐Yeol, Lee, So Jung, Kim, Kang Mo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327222/ https://www.ncbi.nlm.nih.gov/pubmed/32626838 http://dx.doi.org/10.1002/hep4.1523

Ejemplares similares

Effectiveness and Safety of Nivolumab in Child–Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study
por: Choi, Won-Mook, et al.
Publicado: (2020)

Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma
por: Ha, Yeonjung, et al.
Publicado: (2016)

Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis
por: Bang, Yeong Hak, et al.
Publicado: (2022)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
por: Lee, Cheol-Hyung, et al.
Publicado: (2020)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma
por: Choi, Jonggi, et al.
Publicado: (2020)

Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment
por: Jin, Sujin, et al.
Publicado: (2023)

The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment
por: Choi, Jonggi, et al.
Publicado: (2022)

Association between statin use and the prognosis of hepatocellular carcinoma after resection: a nationwide cohort study
por: Jeon, Dongsub, et al.
Publicado: (2023)

A simple and clinically applicable model to predict liver-related morbidity after hepatic resection for hepatocellular carcinoma
por: Choi, Jonggi, et al.
Publicado: (2020)

Development of machine learning-based clinical decision support system for hepatocellular carcinoma
por: Choi, Gwang Hyeon, et al.
Publicado: (2020)

Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation
por: Yoo, Seo Yeon, et al.
Publicado: (2022)

The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE
por: Lim, Jihye, et al.
Publicado: (2021)

Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation
por: Lee, Soon Kyu, et al.
Publicado: (2020)

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program
por: Son, Myoung Kyun, et al.
Publicado: (2017)

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib
por: Oh, Chung Ryul, et al.
Publicado: (2019)

Posttransplant sequential adrenal and spine metastasis of hepatocellular carcinoma responsive to combined regorafenib and radiotherapy: a case report
por: Kim, Jae-Yoon, et al.
Publicado: (2023)

Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
por: Bae, Heewon, et al.
Publicado: (2023)

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
por: Lee, I-Cheng, et al.
Publicado: (2022)

Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma
por: Hong, Young Mi, et al.
Publicado: (2021)

Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients
por: Lee, Sumin, et al.
Publicado: (2022)

Identification of hepatic steatosis in living liver donors by machine learning models
por: Lim, Jihye, et al.
Publicado: (2022)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
por: Park, Sook Ryun, et al.
Publicado: (2016)

Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B
por: Choi, Won-Mook, et al.
Publicado: (2022)

Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion
por: Lee, Danbi, et al.
Publicado: (2018)

Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
por: Kim, Do Young, et al.
Publicado: (2016)

Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity
por: Yoshioka, Naoki, et al.
Publicado: (2019)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

Genetic-based Risk Assessment for Hepatocellular Carcinoma in Patients with Hepatitis C: Where Do We Stand?
por: Choi, Jonggi, et al.
Publicado: (2016)

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
por: Lee, Sung Won, et al.
Publicado: (2021)

The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection
por: Na, Seong Kyun, et al.
Publicado: (2018)

Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
por: D’Alessandro, Rosalba, et al.
Publicado: (2014)

Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers
por: Seo, Seyoung, et al.
Publicado: (2016)

Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion
por: An, Jihyun, et al.
Publicado: (2017)

Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma
por: Zhang, Shun, et al.
Publicado: (2022)

Lamivudine: fading into the mists of time
por: Choi, Jonggi, et al.
Publicado: (2017)

Absence of antitumor effects of metformin in sorafenib-treated patients with hepatocellular carcinoma recurrence after hepatic resection and liver transplantation
por: Chung, Yong-Kyu, et al.
Publicado: (2018)

Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
por: Pelosof, Lorraine, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_59e4mip700claechp4ma6mjt6s